Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.04
  • Today's Change0.045 / 2.26%
  • Shares traded6.65k
  • 1 Year change-52.34%
  • Beta2.1487
Data delayed at least 15 minutes, as of Mar 28 2023 20:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

  • Revenue in USD (TTM)25.73m
  • Net income in USD-90.79m
  • Incorporated2000
  • Employees236.00
  • Location
    Cellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
  • Phone+33 181691600
  • Fax+33 181691606
  • Websitehttp://www.cellectis.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
VolitionRX Ltd306.39k-30.27m108.53m104.00------354.21-0.5478-0.54780.0055-0.04450.0134--7.202,946.06-133.66-102.95-270.09-139.00-----9,986.77-26,254.27---664.582.88--240.28---12.88--1.96--
Trevi Therapeutics Inc0.00-29.15m109.28m25.00--1.02-----0.6459-0.64590.001.790.00----0.00-36.10-62.27-43.07-74.06------------0.0785------14.11--65.00--
Puma Biotechnology Inc228.03m2.00k111.01m192.00--5.1012.440.4868-0.0043-0.00435.100.46621.029.477.711,187,662.000.0009-24.020.0015-39.2675.8481.330.0009-22.631.672.200.8198---9.9252.46100.01---32.63--
BioNexus Gene Lab Corp11.33m-109.75k112.88m8.00--17.57--9.96-0.0006-0.00060.06590.0371.297.743.281,416,801.00-1.25---1.62--11.75---0.9683--3.232.790.0022--17.31---31.31------
Eyenovia Inc10.00m-18.90m113.78m43.00--5.50--11.38-0.5642-0.56420.31680.57220.3546--7.44232,558.10-67.04-82.88-153.31-124.23100.00---189.04-475.55---29.230.2623--600.00--35.36--95.35--
Galectin Therapeutics Inc0.00-35.46m115.88m9.00---------0.5973-0.59730.00-0.37590.00----0.00-126.40-81.15-185.80-97.09-----------160.474.02-------30.07------
Cellectis SA (ADR)25.73m-90.79m116.14m236.00--0.7705--4.51-1.99-2.330.5652.580.08--2.43109,004.20-30.68-21.38-37.76-26.37-85.10-61.60-383.63-268.892.54-10.040.3817---33.35-5.27-5.77---14.21--
CytomX Therapeutics Inc71.94m-97.59m118.29m174.00--4.15--1.64-1.49-1.491.100.43180.2407--55.36413,465.50-32.65-20.40-48.78-26.44-----135.65-103.79----0.00---30.6835.84-154.25---5.86--
Mediwound Ltd26.50m-19.60m118.43m73.00--8.29--4.47-3.85-3.855.321.510.75968.434.77362,958.90-56.19-26.49-83.43-35.2049.6947.32-73.97-42.933.64-0.74670.0719--11.5060.39-44.63---12.39--
Bioatla Inc0.00-106.48m118.54m66.00--0.6565-----2.74-2.740.003.790.00----0.00-44.35---48.71--------------0.00---100.00---11.61------
Gossamer Bio Inc0.00-229.38m119.68m178.00--9.85-----2.74-2.740.000.12790.00----0.00-74.46-61.35-87.05-67.83-----------17.770.9478------1.98------
Chromadex Corp72.05m-16.54m119.74m113.00--4.16--1.66-0.2405-0.24051.030.38451.292.0716.94637,610.60-29.56-54.44-43.29-80.4159.4058.35-22.96-46.661.78--0.0013--6.8227.7239.03---24.39--
INmune Bio Inc374.00k-27.30m120.42m10.00--2.00--321.97-1.52-1.520.02093.350.0041--0.053637,400.00-30.04-38.64-32.80-40.98-----7,299.20-15,877.95---12.890.1965--106.63--10.02------
Akebia Therapeutics Inc292.60m-92.56m120.92m204.00--12.94--0.4133-0.5169-0.51691.590.05070.6671.736.501,434,324.00-21.10-35.87-37.31-52.6582.2569.23-31.63-87.941.31-4.030.8761--37.0010.0667.27---41.20--
Personalis Inc65.05m-113.32m121.98m395.00--0.5588--1.88-2.48-2.481.424.670.18887.283.71164,676.00-32.88-26.39-36.27-33.8320.5229.81-174.20-79.725.77--0.0118---23.9247.26-73.73--57.44--
Milestone Pharmaceuticals Inc1.50m-62.10m123.43m29.00--1.42--82.29-1.47-1.470.03552.540.0137--3.0251,724.14-56.57---59.94-------4,139.67------0.00------14.24------
Data as of Mar 28 2023. Currency figures normalised to Cellectis SA's reporting currency: US Dollar USD

Institutional shareholders

14.57%Per cent of shares held by top holders
HolderShares% Held
Long Focus Capital Management LLCas of 31 Dec 20222.68m4.83%
Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 20221.44m2.59%
Principal Global Investors LLCas of 31 Dec 20221.33m2.40%
Millennium Management LLCas of 31 Dec 2022679.97k1.22%
Baillie Gifford & Co.as of 31 Dec 2022599.90k1.08%
Capital Research & Management Co. (International Investors)as of 31 Dec 2022448.80k0.81%
Capital Research & Management Co. (World Investors)as of 31 Dec 2022250.00k0.45%
D. E. Shaw & Co. LPas of 31 Dec 2022227.11k0.41%
Macquarie Investment Management Business Trustas of 31 Dec 2022226.88k0.41%
Jane Street Capital LLCas of 31 Dec 2022211.47k0.38%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.